Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04184050 · ClinicalTrials.gov registry record · Phase 1
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
A Phase 1 study of Multiple Myeloma and Multiple Myeloma in Relapse, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Active
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 12
- Study locations
NCT04184050 is a Phase 1 study of Multiple Myeloma and Multiple Myeloma in Relapse that is active but no longer recruiting, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT04184050, a Phase 1 study of Multiple Myeloma and Multiple Myeloma in Relapse, is active but no longer recruiting, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 12
- Study locations
Study Summary
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses of MK-4002 in a person's body over time.
Conditions Studied
Interventions
- DRUG MK-4002
Study Locations (12)
Other
- Centre Hospitalier Universitaire De Nantes - Nantes
- Centre Hospitalier Universitaire de Poitiers - Poitiers
- Josep Carreras Leukaemia Research Institute - Barcelona
- Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) - Madrid
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic Arizona - Phoenix
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- University of Rochester James P Wilmot Cancer Institute - Rochester
California
- UC San Diego Moores Cancer Center - La Jolla
Kansas
- The University of Kansas Cancer Center - Fairway
Oregon
- OHSU - Portland
Washington
- University of Washington - Seattle Cancer Center Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-04-13 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04184050
The ClinicalTrials.gov registry entry for NCT04184050 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The listed sponsor is Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which MK-4002 is the first listed.
NCT04184050 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT04184050 about?
NCT04184050 is a clinical study titled "Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)". Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses ...
What is the current status of trial NCT04184050?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2020-04-13. Estimated completion is 2026-12-31.
What conditions does trial NCT04184050 study?
This clinical trial studies the following conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission, Multiple Myeloma of Bone.
What interventions are being tested in trial NCT04184050?
The interventions under investigation include: MK-4002 (DRUG).
Who is sponsoring clinical trial NCT04184050?
This trial is sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04184050 being conducted?
This trial has 12 study locations across Arizona, California, Kansas, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.